High-throughput drug screening identifies compounds and molecular strategies for targeting proteasome inhibitor-resistant multiple myeloma

Leukemia

Volumn 28, Issue 11, 2014, Pages 2263-2267

  Stessman, H A F ^a   Lulla, A ^b   Xia, T ^c   Mitra, A ^a   Harding, T ^a   Mansoor, A ^a   Myers, C L ^d   Van Ness, B G ^a   Dolloff, N G ^b,e  

^a UNIVERSITY OF MINNESOTA   (United States)

^b PENN STATE CANCER INSTITUTE   (United States)

^c HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^d University of Minnesota   (United States)

^e MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; BORTEZOMIB; ENZYME INHIBITOR; PROTEASOME; PYRAZINE DERIVATIVE;

ANIMAL; DRUG RESISTANCE; ENZYMOLOGY; HIGH THROUGHPUT SCREENING; HUMAN; METABOLISM; MOUSE; MULTIPLE MYELOMA; PROCEDURES; TUMOR CELL CULTURE;

ANIMALS; ANTINEOPLASTIC AGENTS; BORONIC ACIDS; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; MICE; MULTIPLE MYELOMA; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRAZINES; TUMOR CELLS, CULTURED;

EID: 84922334607     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2014.214     Document Type: Letter

References (13)

1. Shah JJ, Orlowski RZ. Proteasome inhibitors in the treatment of multiple myeloma. Leukemia 2009; 23: 1964–1979. DOI: 10.1038/leu.2009.173
2. Stessman HA, Baughn LB, Sarver A, Xia T, Deshpande R, Mansoor A et al. Profiling bortezomib resistance identifies secondary therapies in a mouse myeloma model. Mol Cancer Ther 2013; 12: 1140–1150. DOI: 10.1158/1535-7163.MCT-12-1151
3. Stessman HA, Mansoor A, Zhan F, Janz S, Linden MA, Baughn LB et al. Reduced CXCR4 expression is associated with extramedullary disease in a mouse model of myeloma and predicts poor survival in multiple myeloma patients treated with bortezomib. Leukemia 2013; 27: 2075–2077. DOI: 10.1038/leu.2013.148
4. Information NCfB. PubChem BioAssay Database. Available from http://pubchem.ncbi.nlm.nih.gov/assay/assay.cgi?aid=1442.
5. Information NCfB. Available from http://pubchem.ncbi.nlm.nih.gov/assay/assay.cgi?aid=1444.
6. Gong B, Almasan A. Differential upregulation of p53-responsive genes by genotoxic stress in hematopoietic cells containing wild-type and mutant p53. Gene Expr 1999; 8: 197–206.
7. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004; 303: 844–848. DOI: 10.1126/science.1092472
8. Franke NE, Niewerth D, Assaraf YG, van Meerloo J, Vojtekova K, van Zantwijk CH et al. Impaired bortezomib binding to mutant beta5 subunit of the proteasome is the underlying basis for bortezomib resistance in leukemia cells. Leukemia 2012; 26: 757–768. DOI: 10.1038/leu.2011.256
9. Ruckrich T, Kraus M, Gogel J, Beck A, Ovaa H, Verdoes M et al. Characterization of the ubiquitin-proteasome system in bortezomib-adapted cells. Leukemia 2009; 23: 1098–1105. DOI: 10.1038/leu.2009.8
10. Gutman D, Morales AA, Boise LH. Acquisition of a multidrug-resistant phenotype with a proteasome inhibitor in multiple myeloma. Leukemia 2009; 23: 2181–2183. DOI: 10.1038/leu.2009.123
11. Ooi MG, Hayden PJ, Kotoula V, McMillin DW, Charalambous E, Daskalaki E et al. Interactions of the Hdm2/p53 and proteasome pathways may enhance the antitumor activity of bortezomib. Clin Cancer Res 2009; 15: 7153–7160. DOI: 10.1158/1078-0432.CCR-09-1071
12. Saha MN, Jiang H, Jayakar J, Reece D, Branch DR, Chang H. MDM2 antagonist nutlin plus proteasome inhibitor velcade combination displays a synergistic anti-myeloma activity. Cancer Biol Ther 2010; 9: 936–944. DOI: 10.4161/cbt.9.11.11882
13. Jin L, Tabe Y, Kojima K, Zhou Y, Pittaluga S, Konopleva M et al. MDM2 antagonist Nutlin-3 enhances bortezomib-mediated mitochondrial apoptosis in TP53-mutated mantle cell lymphoma. Cancer Lett 2010; 299: 161–170. DOI: 10.1016/j.canlet.2010.08.015